TQB6426 / Sino Biopharm - LARVOL DELTA

TQB6426-I-01: A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=151 | Not yet recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

New P1 trial • Oncology • Solid Tumor • GPC3

TQB6426-I-01: A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=151 | Recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Oncology • Solid Tumor • GPC3

Sino Biopharmaceutical…announces that TQB6426 'GPC3 antibody-drug conjugate (ADC)', a national Category 1 new drug self-developed by Chia Tai Tianqing Pharmaceutical…has received an investigational new drug (IND) approval from the U.S. Food and Drug Administration (FDA), intended for advanced malignant tumors (HKEXnews) - "The Group will accelerate the Phase I clinical trial of TQB6426 to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy in patients with advanced malignant tumors, with the aim of providing new treatment options for patients with HCC and other solid tumors in the world as early as possible."

IND • New P1 trial • Hepatocellular Cancer